tiprankstipranks
GeneTether Therapeutics, Inc. (TSE:GTTX)
CNQX:GTTX
Canadian Market
Holding TSE:GTTX?
Track your performance easily

GeneTether Therapeutics, Inc. (GTTX) Income Statement

3 Followers

GeneTether Therapeutics, Inc. Income Statement

Last quarter (Q2 2024), GeneTether Therapeutics, Inc.'s total revenue was $―, a decrease of ― from the same quarter last year. In Q2, GeneTether Therapeutics, Inc.'s net income was $-107.79K. See GeneTether Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20
Total Revenue
----$ 0.00
Cost of Revenue
-----
Gross Profit
-----
Operating Expense
$ 658.43K$ 747.28K$ 1.72M$ 1.64M$ 71.96K
Operating Income
$ -658.43K$ -747.28K$ -1.72M$ -1.64M$ -71.96K
Net Non Operating Interest Income Expense
$ 55.17K$ 52.16K$ 4.84K$ -282.00$ -1.00K
Other Income Expense
--$ -2.86K--
Pretax Income
$ -595.72K$ -688.36K$ -1.72M$ -1.64M$ -72.97K
Tax Provision
-----
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -595.81K$ -688.36K$ -1.72M$ -1.64M$ -72.97K
Basic EPS
$ -0.01$ -0.01$ -0.04$ -0.05$ >-0.01
Diluted EPS
$ -0.01$ -0.01$ -0.04$ -0.05$ >-0.01
Basic Average Shares
$ 166.06M$ 46.41M$ 43.07M$ 35.76M$ 47.78M
Diluted Average Shares
$ 166.06M$ 46.41M$ 43.07M$ 35.76M$ 47.78M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 658.43K$ 747.28K$ 1.72M-$ 71.96K
Net Income From Continuing And Discontinued Operation
$ -595.81K$ -688.36K$ -1.72M$ -1.64M$ -72.97K
Normalized Income
$ -502.11K$ -505.94K$ -1.26M$ -1.20M$ -72.97K
Interest Expense
----$ 1.00K
EBIT
$ -595.81K$ -688.36K$ -1.72M$ -1.64M$ -71.96K
EBITDA
$ -595.81K$ -688.36K$ -1.72M$ -1.64M$ -71.96K
Currency in USD

GeneTether Therapeutics, Inc. Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis